Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what discussions the Government has had with representatives of the United States on the pricing of medicines for the NHS in the last six months.

The pharmaceutical sector and the innovative medicines it produces are critical to our national interest, helping people to access life changing treatments, reducing pressure on the health service over the longer-term, and ensuring we have a National Health Service that is fit for the future.

Thanks to the strength of our relationship with the United States, we have secured the first and only deal with them that delivers 0% tariffs on pharmaceutical products, the lowest rate offered to any country. This deal secures the United Kingdom’s access to and supply of medicines for tens of thousands of patients while safeguarding our supply chain and ensuring groundbreaking new treatments will reach the NHS front line quicker. It also delivers mitigations on the US’ ‘Most Favoured Nation’ policy and preferential terms for UK MedTech exports, helping expand access innovative treatments for patients and driving crucial investment in the UK.